A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
A cross-party group of politicians have teamed up to launch a campaign to "take a stand" against online abuse.
Months of messages contradict the public claims of doctors during the dispute and reveal pay was central to their row with the Government.
An amazing trove of 4,000 photos which lay undiscovered for a century show the faces of First World War soldiers on the eve of battle.